tiprankstipranks

Korro Bio price target lowered to $53 from $130 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $53 from $130 and keeps a Buy rating on the shares. The company reported Q1 results and announced a 20% workforce reduction to extend its cash runway into 2027 from the second half of 2026, the analyst tells investors in a research note. The firm believes Korro’s catalysts are on track but adjusted its model to reflect the “increasingly competitive” alpha-1 antitrypsin deficiency landscape.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue